Advertisement

Clinical and Experimental Nephrology

, Volume 17, Issue 3, pp 365–371 | Cite as

Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease

  • Shunsuke Goto
  • Ken Kitamura
  • Keiji Kono
  • Kentaro Nakai
  • Hideki Fujii
  • Shinichi Nishi
Original Article

Abstract

Background

Vascular calcification is associated with mortality and cardiovascular events in patients with chronic kidney disease. AST-120, which adsorbs uremic toxins, is reported to reduce the risk of cardiovascular disease and death in chronic kidney disease patients. The aim of the current study was to investigate the association between abdominal aortic calcification and the use of AST-120 in predialysis chronic kidney disease patients.

Methods

A retrospective analysis was conducted including 199 predialysis chronic kidney disease patients (stages 4 and 5) who underwent abdominal plain computed tomography in our institution between 2005 and 2010. Abdominal aortic calcification was assessed by aortic calcification index (ACI). Patients were divided into two groups based on whether or not AST-120 was administered for at least six months, and ACI was compared between the two groups.

Results

The aortic calcification index was significantly lower in patients taking AST-120 [12.2 (2.5–30.3) vs. 25.7 (13.4–45.3) %, P < 0.001]. According to multivariate linear regression analysis, the use of AST-120 was independently and significantly correlated with ACI after adjusting for confounding factors.

Conclusions

The use of AST-120 was independently associated with less aortic calcification in predialysis chronic kidney disease patients.

Keywords

AST-120 Chronic kidney disease Uremic toxins Vascular calcification 

Notes

Acknowledgments

We thank Masako Morii for assisting with data collection. Preliminary results of this study were presented in part at the American Society of Nephrology Kidney Week 2011 Annual Meeting in Philadelphia, PA, USA, on November 10, 2011.

Conflict of interest

HF has received research grants from Kureha Corporation.

References

  1. 1.
    Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, Kitazawa S, Fukagawa M. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24:2089–95.PubMedCrossRefGoogle Scholar
  2. 2.
    Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, Koide H. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res. 2004;27:121–6.Google Scholar
  3. 3.
    Nakai K, Fujii H, Kono K, Goto S, Fukagawa M, Nishi S. Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol. 2011;33:218–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail. 2008;30:856–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Niwa T, Emoto Y, Maeda K, Uehara Y, Yamada N, Shibata M. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol Dial Transplant. 1991;6:105–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant. 2008;23:1892–901.PubMedCrossRefGoogle Scholar
  7. 7.
    Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4:1551–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators Developing the Japanese Equation for Estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.Google Scholar
  9. 9.
    Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J. 1973;4:643–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Hanada S, Ando R, Naito S, Kobayashi N, Wakabayashi M, Hata T, Sasaki S. Assessment and significance of abdominal aortic calcification in chronic kidney disease. Nephrol Dial Transplant. 2010;25:1888–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Taniwaki H, Ishimura E, Tabata T, Tsujimoto Y, Shioi A, Shoji T, Inaba M, Inoue T, Nishizawa Y. Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 2005;20:2472–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004;8:54–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Ohtake T, Ishioka K, Honda K, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Hidaka S, Kobayashi S. Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis. Hemodial Int. 2010;14:218–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Shimoyama Y, Tsuruta Y, Niwa T. Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. J Ren Nutr. 2012;22:139–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K, Yamakawa T, Imanishi Y, Inaba M, Nishizawa Y. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007;49:417–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Verbeke F, Van Biesen W, Honkanen E, Wikström B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL, CORD Study Investigators. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol. 2011;6:153–9.PubMedCrossRefGoogle Scholar
  18. 18.
    London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:1241–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis. 2006;47:565–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Niwa T, Tsukushi S, Ise M, Miyazaki T, Tsubakihara Y, Owada A, Shiigai T. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab. 1997;23:179–84.PubMedGoogle Scholar
  22. 22.
    Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, Fujimura A, Asano Y, Kusano E. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69:1780–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009;24:2051–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004;65:442–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Tumur Z, Niwa T. Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol. 2009;29:551–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol. 2010;31:435–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B. 2010;878:2997–3002.Google Scholar
  28. 28.
    Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, Wu MS. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients—a prospective cohort study. Nephrol Dial Transplant. 2012;27:1169–75.PubMedCrossRefGoogle Scholar
  29. 29.
    Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008;73:1174–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25:3693–700.PubMedCrossRefGoogle Scholar
  31. 31.
    Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010;5:1182–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Yamakado M, Ise M. Mechanism of oral absorbent AST-120 in lipid abnormalities in experimental uremic rats. Kidney Int Suppl. 1999;71:S190–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Aoyama I, Miyazaki T, Takayama F. Oral adsorbent ameliorates renal TGF-beta 1 expression in hypercholesterolemic rats. Kidney Int Suppl. 1999;71:S193–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K, CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459–67.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Shunsuke Goto
    • 1
  • Ken Kitamura
    • 1
  • Keiji Kono
    • 1
  • Kentaro Nakai
    • 1
  • Hideki Fujii
    • 1
  • Shinichi Nishi
    • 1
  1. 1.Division of Nephrology and Kidney CenterKobe University Graduate School of MedicineKobeJapan

Personalised recommendations